Further Steps in the Development of Pharmacoeconomics, Outcomes Research, and Health Technology Assessment in Central and Eastern Europe, Western Asia, and Africa.

[1]  J. Sosna,et al.  Cost-effectiveness of baseline low-dose computed tomography screening for lung cancer: the Israeli experience. , 2013, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[2]  M. Ferraz,et al.  Status Update of the Reimbursement Review Environment in the Public Sector across Four Latin American Countries. , 2012, Value in health regional issues.

[3]  S. Resch,et al.  Performing Country-led Economic Evaluations to Inform Immunization Policy: ProVac Experiences in Latin America and the Caribbean. , 2012, Value in health regional issues.

[4]  Z. Kaló,et al.  Attempt to increase the transparency of fourth hurdle implementation in Central-Eastern European middle income countries: publication of the critical appraisal methodology , 2012, BMC Health Services Research.

[5]  Stephen S. Lim,et al.  Generalized Cost-Effectiveness Analysis of Pharmaceutical Interventions for Primary Prevention of Cardiovascular Disease in Thailand. , 2012, Value in health regional issues.

[6]  Bong-min Yang,et al.  Cost-Effectiveness of Sertindole among Atypical Antipsychotics in the Treatment of Schizophrenia in South Korea. , 2012, Value in health regional issues.

[7]  Z. Kaló,et al.  Modeling cost-effectiveness of cervical cancer screening in Hungary. , 2012, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[8]  J. Pliskin,et al.  The process of updating the National List of Health Services in Israel: Is it legitimate? Is it fair? , 2009, International Journal of Technology Assessment in Health Care.

[9]  I. Kriszbacher,et al.  The disease burden of colorectal cancer in Hungary , 2009, The European Journal of Health Economics.

[10]  I. Boncz,et al.  Financial deficits in the health services of the UK and Hungary , 2006, The Lancet.